Sign In
Buy PLSE
$24.99
+0.710 (+2.92%)
At Close: Jun 03, 2026
Pulse Biosciences Gets FDA IDE Nod for Atrial Fibrillation Study
01:26pm, Thursday, 11'th Sep 2025
PLSE wins FDA IDE approval for its NANOCLAMP AF study, advancing nsPFA tech as a novel option in atrial fibrillation surgery.
Pulse Biosciences' nPulse™ Technology to be Featured at the American Thyroid Association 2025 Annual Meeting
07:00am, Wednesday, 10'th Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation�
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Thursday, 04'th Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Announces First Successful Procedures in PRECISE Benign Thyroid Nodule (BTN) Study
07:00am, Tuesday, 02'nd Sep 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
PLSE Shares Rise on First-in-Human Data for Thyroid Nodule Treatment
01:26pm, Wednesday, 27'th Aug 2025
Pulse Biosciences shares rise on first-in-human study showing its nsPFA tech cuts thyroid nodule size with strong safety and efficacy.
Pulse Biosciences Announces Publication of First-In-Human Data for Treatment of Benign Thyroid Nodules in the Journal Thyroid
07:00am, Tuesday, 26'th Aug 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences, Inc. (PLSE) Q2 2025 Earnings Call Transcript
09:06pm, Tuesday, 12'th Aug 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Jon Skinner - Chief Financial Officer Paul Arthur LaViolette - President, CEO, P
Pulse Biosciences Reports Business Updates and Second Quarter 2025 Financial Results
04:05pm, Tuesday, 12'th Aug 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences To Present at the 45th Canaccord Genuity Annual Growth Conference
07:00am, Friday, 01'st Aug 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Schedules Second Quarter 2025 Business Updates and Financial Results Conference Call for August 12, 2025
04:05pm, Tuesday, 29'th Jul 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Wednesday, 16'th Jul 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 23'rd May 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
Pulse Biosciences, Inc. (PLSE) Q1 2025 Earnings Call Transcript
11:02pm, Saturday, 10'th May 2025
Pulse Biosciences, Inc. (NASDAQ:PLSE ) Q1 2025 Earnings Call May 8, 2025 4:30 PM ET Company Participants Philip Taylor - Gilmartin Group Jon Skinner – CFO Paul LaViolette – CEO and Co-Chairman of
Pulse Biosciences Reports Business Updates and First Quarter 2025 Financial Results
04:05pm, Thursday, 08'th May 2025
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, to
